According to recent updates to global cancer statistics and analyses of the global cancer database published by the International Agency for Research on Cancer, prostate cancer remains one of the most common malignant tumors in men worldwide. The latest research estimates that by around 2025, there will be approximately 1.46 million new cases of prostate cancer globally each year, with about 0.39million to 0.4million deaths, and a global age-standardized incidence rate of approximately 29,400 men.
In terms of regional distribution, the incidence of prostate cancer still shows significant geographical differences: North America, Oceania, and Europe have the highest incidence rates, while Asia and Africa have relatively low rates overall.
In developed regions such as North America, Oceania, and Europe, the incidence of prostate cancer has long been among the highest in the world. For example, in the United States, the age-standardized incidence rate is approximately 75,000 men; in France, it can reach over 80,000. This phenomenon is generally related to the widespread use of PSA (prostate-specific antigen) screening, population aging, and Western lifestyles such as high-fat diets.
In contrast, the overall incidence rate in Asia is significantly lower, with most countries reporting between 10,000 and 30,000 male cases, but regional differences are evident. For example, in Japan, with the aging population, prostate cancer has become one of the most common cancers among men. The National Cancer Center of Japan predicts approximately 99,900 new cases by 2025, making it the leading cause of cancer death among men.
On the other hand, in regions with relatively insufficient medical resources, such as the Caribbean, Central Africa, and West Africa, although the overall incidence rate may not be the highest, the mortality rate is among the highest in the world, with some countries experiencing mortality rates exceeding 20,000 to 30,000 men. This difference is mainly related to insufficient screening, late diagnosis, and limited treatment resources.
In addition, in regions such as Central Europe and Eastern Europe, although the overall incidence rate is lower than in Western Europe, the mortality rate has been rising in recent years. This is closely related to insufficient screening coverage, population aging, and uneven distribution of medical resources.
Overall, prostate cancer globally exhibits a typical epidemiological pattern of "high incidence in developed regions and high mortality in developing regions".
Most prostate cancer patients are over 65 years old and often experience prostate enlargement. The vast majority of these enlargements are benign, but if the cells undergo gene mutations and become malignant, it develops into prostate cancer. The main reasons are as follows:
1. Age Factor: Age is the most important risk factor for prostate cancer, with approximately 60% of diagnosed patients being over 65 years of age. With increasing age, the ability of prostate cells to repair DNA declines, increasing the risk of accumulated gene mutations.
2. Family genetic factors: Approximately 5%-10% of prostate cancers are related to genetics. If a first-degree relative has the disease, the individual's risk increases by 2-3 times. BRCA1/2 gene mutations and HOXB13 gene abnormalities have also been shown to be associated with the disease.
3. Racial differences: The incidence rate among African American men is significantly higher than that among Caucasians and Asians, which may be related to genetic differences, social environment, and access to medical resources.
4. Hormone Levels: Androgens (such as testosterone) play a crucial role in prostate cell growth. High androgen levels may promote cancer cell proliferation, while androgen-suppressing therapies have been used clinically to control the disease.
5. Diet and Obesity: A high-fat diet (especially red meat and dairy products) may increase the risk, while a diet rich in tomatoes (containing lycopene) and cruciferous vegetables has a protective effect. Obese individuals have elevated levels of inflammatory factors, which may accelerate the development of cancer cells.
6. Environmental and Chemical Exposure: Individuals with long-term exposure to herbicides, industrial chemicals (such as cadmium and benzene), or those undergoing pelvic radiation therapy have a higher risk of developing the disease than the general population.
7. Controversial Factors: Some studies suggest that chronic prostatitis and sexually transmitted infections may be associated with cancer, but the evidence is insufficient. Furthermore, while smoking does not directly cause cancer, it can exacerbate disease progression by inducing DNA oxidative damage.
Prostate cancer often lacks specific symptoms in its early stages, and many patients are only diagnosed during physical examinations or prostate-specific antigen (PSA) tests. As the tumor progresses, patients may experience a range of urinary tract-related symptoms, such as difficulty urinating, urinary frequency, increased nocturia, or a weak urine stream. These may be accompanied by local discomfort: perineal soreness, testicular pain, lower back pain, and even sexual dysfunction symptoms, such as erectile dysfunction or painful ejaculation. These symptoms can sometimes resemble those of common conditions like benign prostatic hyperplasia (BPH), and should not be ignored.
So how can we prevent prostate cancer in its early stages?
For high-risk groups (such as men over 50 or those with a family history), regular PSA (prostate-specific antigen) testing and digital rectal examinations are recommended. Lifestyle adjustments such as maintaining a healthy weight, reducing saturated fat intake, and increasing fruit and vegetable consumption may lower the risk of developing the disease.
In addition, prolonged sitting in men can increase the risk of prostatitis or benign prostatic hyperplasia (BPH) by compressing the prostate and affecting local blood circulation and metabolism. Maintaining a sitting posture for extended periods can lead to pelvic congestion and the accumulation of metabolic waste, potentially inducing inflammation or tissue hyperplasia. Regular movement and exercise are recommended to reduce these risks.
Scientific Prevention and Improvement Strategies
1. Change Body Position Regularly
Get up and move around for 3-5 minutes every 40-60 minutes. You can choose to stand while working, walk around to get water, etc. During lunch break, adopt a side-lying position to reduce pelvic floor pressure.
2. Targeted Exercise Regulation
Squat Training: 3 sets of 15 repetitions each day to improve pelvic floor muscle pumping function;
Kegel Exercises: Contract the anus for 3 seconds, then relax, repeat 10-15 times per set, 2-3 sets daily. This can be used in conjunction with the Comfly wearable massager. Adjust the massage head to a suitable angle and stand while rocking up and down. Regular exercise can not only help prevent prostate cancer but also improve male sexual dysfunction and other urological conditions;
Aerobic Exercise: Brisk walking/swimming 3 times a week for at least 30 minutes each time to promote overall blood circulation;
3. Avoid aggravating factors:
Avoid holding urine while sitting for extended periods (bladder pressure is transmitted to the prostate);
Reduce activities that continuously compress the perineum, such as cycling;
Control spicy foods and alcohol intake (stimulate gland congestion);
4. Daily health care points:
Drink 1500-2000ml of water daily to dilute urine concentration;
Choose a seat cushion with a perforated center to distribute pressure;
Have regular checkups (PSA test, digital rectal exam), annually recommended for those over 40;
In summary, the occurrence of prostate cancer is closely related to a variety of factors, including age, genetic factors, lifestyle, and environmental factors. Although some risk factors are difficult to completely avoid, establishing a healthy lifestyle, maintaining a reasonable diet, increasing physical exercise, and having regular prostate-related examinations can, to some extent, reduce the risk of disease and improve the early detection rate.